المؤلفون: Farah Raheem, Suganya Arunachalam Karikalan, Felipe Batalini, Aya El Masry, Lida Mina

المصدر: International Journal of Molecular Sciences, Vol 24, Iss 22, p 16198 (2023)

مصطلحات موضوعية: endocrine resistance, ER+ breast cancer, ESR1 mutations, PIK3CA mutations, PI3K/Akt/mTOR pathway, MAPK pathway, Biology (General), QH301-705.5, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/24/22/16198Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/36af0333fe38426aa82142cea76ea66fTest

المؤلفون: Tolaney, Sara M., Chan, Arlene, Petrakova, Katarina, Delaloge, Suzette, Campone, Mario, Iwata, Hiroji, Peddi, Parvin F., Kaufman, Peter A., De Kermadec, Elisabeth, Liu, Qianying, Cohen, Patrick, Paux, Gautier, Wang, Lei, Ternès, Nils, Boitier, Eric, Im, Seock-Ah

المساهمون: Im, Seock-Ah

مصطلحات موضوعية: DOUBLE-BLIND, ESR1 MUTATIONS, FULVESTRANT, THERAPY, WOMEN, MULTICENTER, REGIMENS

العلاقة: Journal of Clinical Oncology, Vol.41 No.24, pp.4014-4024; https://hdl.handle.net/10371/195841Test; 001058339300009; 2-s2.0-85168243232; 191569

الإتاحة: https://doi.org/10.1200/JCO.22.02746Test
https://hdl.handle.net/10371/195841Test

المؤلفون: Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori

المصدر: Diagnostics; Volume 13; Issue 12; Pages: 2040

مصطلحات موضوعية: ESR1 mutations, breast cancer, peptide nucleic acid and locked nucleic acid polymerase chain reaction, next-generation sequencing, circulating tumour DNA

وصف الملف: application/pdf

العلاقة: Pathology and Molecular Diagnostics; https://dx.doi.org/10.3390/diagnostics13122040Test

الإتاحة: https://doi.org/10.3390/diagnostics13122040Test

المؤلفون: M. A. Frolova, M. B. Stenina, М. А. Фролова, М. Б. Стенина

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 41-47 ; Медицинский Совет; № 11 (2023); 41-47 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: алпелисиб, fulvestrant, selective estrogen receptor degraders, ESR1 mutations, PIK3CA mutations, alpelisib, фулвестрант, селективные дегрейдеры рецепторов эстрогена, ESR1 мутации, PIK3CA мутации

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7667/6801Test; Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412Test.; Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. https://doi.org/10.1146/annurevmed-070909-182917Test.; Gottardis M.M., Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183–5187. Available at: https://pubmed.ncbi.nlm.nih.gov/3409244Test/.; Gottardis M.M., Wagner R.J., Borden E.C., Jordan V.C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in Vivo and in Vitro. Cancer Res. 1989;49(17):4765–4769. Available at: https://pubmed.ncbi.nlm.nih.gov/2758410Test/.; Gottardis M.M., Jiang S.-Y., Jeng M.-H., Jordan V.С. Inhibition of tamoxifenstimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090–4093. Available at: https://pubmed.ncbi.nlm.nih.gov/2743303Test/.; Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.С. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990;50(11): 3189–3192. Available at: https://pubmed.ncbi.nlm.nih.gov/2334915Test/.; Bowler J., Lilley T.J., Pittam J.D., Wakeling A.E. Novel steroidal pure antiestrogens. Steroids. 1989;54(1):71–99. https://doi.org/10.1016/0039-128xTest(89)90076-7.; Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–3873. Available at: https://pubmed.ncbi.nlm.nih.gov/1855205Test/.; Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106(Pt 4):1377–1388. https://doi.org/10.1242/jcs.106.4.1377Test.; Osborne C.K., Wakeling A., Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(1 Suppl.):S2–S6. https://doi.org/10.1038/sj.bjc.6601629Test.; Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000;89(4):817–825. https://doi.org/10.1002/1097-0142Test(20000815)89:43.0.co;2-6.; Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B. et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8(1):21–30. https://doi.org/10.1210/mend.8.1.8152428Test.; Nicholson R.I., Gee J.M., Manning D.L., Wakeling A.E., Montano M.M., Katzenellenbogen B.S. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 1995;761:148–163. https://doi.org/10.1111/j.1749-6632.1995.tb31376.xTest.; Harrison M., Laight A., Clarke D., Giles P., Yates Y. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. EJC. 2003;1(5):S171. https://doi.org/10.1016/s1359-6349Test(03)90596-9.; Robertson J.F., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol. 2003;52(4):346–348. https://doi.org/10.1007/s00280-003-0643-7Test.; McCormack P., Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor–positive advanced breast cancer. Clin Breast Cancer. 2008;8(4):347–351. https://doi.org/10.3816/CBC.2008.n.040Test.; Ohno S., Rai Y., Iwata H., Yamamoto N., Yoshida M., Iwase H. et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–2347. https://doi.org/10.1093/annonc/mdq249Test.; Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396–3403. https://doi.org/10.1200/JCO.2002.10.057Test.; Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058Test.; Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605–1613. https://doi.org/10.1200/JCO.2004.02.112Test.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600. https://doi.org/10.1200/JCO.2010.28.8415Test.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337. https://doi.org/10.1093/jnci/djt337Test.; Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E. et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–4535. https://doi.org/10.1200/JCO.2008.21.1136Test.; Robertson J.F., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. https://doi.org/10.1016/S0140-6736Test(16)32389-3.; Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. https://doi.org/10.1200/JCO.2017.75.6155Test.; Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303Test.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., PaluchShimon S. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709Test.; Sledge G.W. Jr, Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. https://doi.org/10.1200/JCO.2017.73.7585Test.; Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. https://doi.org/10.1016/S1470-2045Test(15)00613-0.; Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909Test.; Llombart-Cussac A., Pérez-García J.M., Bellet M., Dalenc F., Gil-Gil M., RuízBorrego M. et al. PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–1799. https://doi.org/10.1001/jamaoncol.2021.4301Test.; Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L. et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998. https://doi.org/10.1016/S1470-2045Test(13)70322-X.; Fribbens C., O’Leary B., Kilburn L., Hrebien S., Garcia-Murillas I., Beaney M. et al. Plasma ESR1 mutations and the treatment of estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–2968. https://doi.org/10.1200/JCO.2016.67.3061Test.; Giuliano M., Schettini F., Rognoni C., Milani M., Jerusalem G., Bachelot T. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. https://doi.org/10.1016/S1470-2045Test(19)30420-6.; Wilson F.R., Varu A., Mitra D., Cameron C., Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167–177. https://doi.org/10.1007/s10549-017-4404-4Test.; André F., Ciruelos E., Rubovszky G., Campone M., Rugo H.S., Iwata H. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904Test.; Rugo H.S., Neven P., Saffie I., Park Y.H., De Laurentiis M., Lerebours F. et al. Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2– advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses. Cancer Res. 2022;82(4):PD13–05. https://doi.org/10.1158/1538-7445.SABCS21-PD13-05Test.; https://www.med-sovet.pro/jour/article/view/7667Test

الإتاحة: https://doi.org/10.21518/ms2023-189Test
https://doi.org/10.1038/nature11412Test
https://doi.org/10.1146/annurevmed-070909-182917Test
https://doi.org/10.1016/0039-128xTest(89)90076-7
https://doi.org/10.1242/jcs.106.4.1377Test
https://doi.org/10.1038/sj.bjc.6601629Test
https://doi.org/10.1002/1097-0142Test(20000815)89:4<817::aid-cncr14>3.0.co;2-6
https://doi.org/10.1210/mend.8.1.8152428Test
https://doi.org/10.1111/j.1749-6632.1995.tb31376.xTest
https://doi.org/10.1016/s1359-6349Test(03)90596-9

المؤلفون: Pancholi, S, Simigdala, N, Ribas, R, Schuster, E, Leal, MF, Nikitorowicz-Buniak, J, Rega, C, Bihani, T, Patel, H, Johnston, SR, Dowsett, M, Martin, L-A

المساهمون: Schuster, Eugene

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Oncology, ESR1 MUTATIONS, ANTITUMOR-ACTIVITY, DEGRADER SERD, DOUBLE-BLIND, EXPRESSION, RAD1901, FOXA1, POSTMENOPAUSAL, THERAPY, EFFICACY

جغرافية الموضوع: United States

وصف الملف: Electronic; application/pdf

العلاقة: ARTN 125; npj Breast Cancer, 2022, 8 (1), pp. 125 -; https://repository.icr.ac.uk/handle/internal/5695Test

الإتاحة: https://doi.org/10.1038/s41523-022-00483-1Test
https://repository.icr.ac.uk/handle/internal/5695Test

المؤلفون: Cani, Andi K., Dolce, Emily M., Darga, Elizabeth P., Hu, Kevin, Liu, Chia-Jen, Pierce, Jackie, Bradbury, Kieran, Kilgour, Elaine, Aung, Kimberly, Schiavon, Gaia, Carroll, Danielle, Carr, T. Hedley, Klinowska, Teresa, Lindemann, Justin, Marshall, Gayle, Rowlands, Vicky, Harrington, Elizabeth A., Barrett, J. Carl, Sathiyayogan, Nitharsan, Morrow, Christopher, Sero, Valeria, Armstrong, Anne C., Baird, Richard, Hamilton, Erika, Im, Seock-Ah, Jhaveri, Komal, Patel, Manish R., Dive, Caroline, Tomlins, Scott A., Udager, Aaron M., Hayes, Daniel F., Paoletti, Costanza

المساهمون: Im, Seock-Ah

مصطلحات موضوعية: COPY NUMBER ALTERATIONS, FULVESTRANT 500 MG, DIAGNOSTIC LEUKAPHERESIS, POSTMENOPAUSAL WOMEN, MOLECULAR ANALYSIS, ESR1 MUTATIONS, EVOLUTION, SINGLE, SURVIVAL, PROGRESSION, circulating tumor cells, circulating tumor DNA, liquid biopsy, precision medicine, tumor evolution, tumor heterogeneity

العلاقة: Molecular Oncology, Vol.16 No.10, pp.1969-1985; https://hdl.handle.net/10371/189452Test; 000731836800001; 2-s2.0-85121418307; 158580

الإتاحة: https://doi.org/10.1002/1878-0261.13150Test
https://hdl.handle.net/10371/189452Test

المؤلفون: Dimitra Stergiopoulou, Athina Markou, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Stylianos Kakolyris, Sabine Kasimir-Bauer, Evi Lianidou

المصدر: Cancers; Volume 14; Issue 15; Pages: 3790

مصطلحات موضوعية: liquid biopsy, cell-free DNA, cfDNA, circulating tumor DNA, ctDNA, ESR1 mutations, ovarian cancer, droplet digital PCR, drop-off ddPCR

وصف الملف: application/pdf

العلاقة: Cancer Biomarkers; https://dx.doi.org/10.3390/cancers14153790Test

الإتاحة: https://doi.org/10.3390/cancers14153790Test

المؤلفون: Harrod, A, Lai, C, Goldsbrough, I, Simmons, G, Oppermans, N, Santos, D, Gyorffy, B, Allsopp, R, Toghill, B, Balachandran, K, Lawson, M, Morrow, C, Surakala, M, Carnevalli, L, Zhang, P, Guttery, D, Shaw, J, Coombes, RC, Buluwela, L, Ali, S

المساهمون: Breast Cancer Care & Breast Cancer Now, Medical Research Council (MRC), Cancer Research UK

المصدر: 4915 ; 4905

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Biochemistry & Molecular Biology, Oncology, Cell Biology, Genetics & Heredity, LIGAND-BINDING DOMAIN, ACQUIRED ENDOCRINE RESISTANCE, ACTIVATING ESR1 MUTATIONS, ALPHA MUTATIONS, THERAPEUTIC VULNERABILITIES, AROMATASE INHIBITORS, CELLS, ANTAGONISM, LANDSCAPE, STABILITY, Humans, Female, Receptors, Estrogen, Breast Neoplasms, Estrogen Receptor alpha, Prognosis, Estrogen Antagonists, Mutation, Estrogens, Oncology & Carcinogenesis, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis

العلاقة: Oncogene; http://hdl.handle.net/10044/1/99787Test; 2014MayPR234; MR/P018521/1; C37/A18784; 12011

الإتاحة: https://doi.org/10.1038/s41388-022-02483-8Test
http://hdl.handle.net/10044/1/99787Test

المؤلفون: Negi, Arvind, Kesari, Kavindra Kumar, Voisin-Chiret, Anne Sophie

المساهمون: Textile Chemistry, Department of Bioproducts and Biosystems, Université de Caen, Department of Applied Physics, Aalto-yliopisto, Aalto University

مصطلحات موضوعية: peptide PROTACs, SNIPERs, PORTACs, antibody-based PROTAC conjugate, clinical PROTACs, GROWTH-FACTOR-I, NF-KAPPA-B, PROSTATE-CANCER PROGRESSION, PROTEIN-PROTEIN INTERACTION, ACTIVATING ESR1 MUTATIONS, BETA-AGONISTS SERBAS, ER-ALPHA, SMALL MOLECULES, BINDING DOMAIN, BREAST-CANCER

وصف الملف: application/pdf

العلاقة: PHARMACEUTICS; Volume 14, issue 11; Negi , A , Kesari , K K & Voisin-Chiret , A S 2022 , ' Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs ' , PHARMACEUTICS , vol. 14 , no. 11 , 2523 , pp. 1-43 . https://doi.org/10.3390/pharmaceutics14112523Test; PURE UUID: 9508460c-f858-4524-9cda-10df0e3b592d; PURE ITEMURL: https://research.aalto.fi/en/publications/9508460c-f858-4524-9cda-10df0e3b592dTest; PURE LINK: http://www.scopus.com/inward/record.url?scp=85146599229&partnerID=8YFLogxKTest; PURE FILEURL: https://research.aalto.fi/files/97688199/Estrogen_Receptor_Targeting.pdfTest; https://aaltodoc.aalto.fi/handle/123456789/118920Test; URN:NBN:fi:aalto-202301181276

الإتاحة: https://doi.org/10.3390/pharmaceutics14112523Test
https://aaltodoc.aalto.fi/handle/123456789/118920Test

المؤلفون: Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang SS

المصدر: Cancer Management and Research, Vol Volume 10, Pp 2573-2580 (2018)

مصطلحات موضوعية: metastatic breast cancer, ESR1 mutations, cell-free DNA, circulating tumor DNA, meta-analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/clinical-value-of-circulatingTest-esr1-mutations-for-patients-with-metasta-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322Test

الوصول الحر: https://doaj.org/article/07504a8dae75421b80f333c3c54d98d7Test